

**GENAISSE
PHARMACEUTICALS**

166-2

Genaissance Pharmaceuticals, Inc.
Five Science Park
New Haven, CT 06511

Telephone: (203) 773-1450
Fax: (203) 562-9377

www.genaissance.com

To: Karen Williams Date: November 6, 2001

Company: USPTO Pages: 3

Fax Number: 1-703-305-3230

From: Gisela M. Field *Gisela M. Field*

Subject: excess claims fees for 09/856,803

Comments:

Dear Ms. Williams,

This fax is in regards to our telephone conversation last week regarding the excess claims fees for the above referenced US Application. The second page of the Notice of Acceptance of Application under 35 USC 371 and 37 CFR 1.494 or 1.495 mailed October 23, 2001 noted that excess claims fees were due in the amount of \$36. I hereby authorize the USPTO to charge these excess claims fees to our deposit account 50-1293 as originally instructed in the transmittal letter and amendment (see attached pages). If you should have any further questions or if I can be of further assistance, please call me at 1-203-786-3473.

Thank you very much for your assistance.

URGENT

PLEASE HAND DELIVER TO KAREN WILLIAMS

The document(s) accompanying this facsimile contain(s) information from Genaissance Pharmaceuticals that is confidential, proprietary, and/or legally privileged. The information is intended only for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or the taking of any action in reliance on the contents of this faxed information is strictly prohibited, and the document(s) should be returned to this company immediately. If you have received this fax in error, please notify us by telephone immediately, so that we may arrange for the return of the original document(s) at no cost to you.

U.S. APPLICATION NO. (if known, 37 CFR 1.45)	INTERNATIONAL APPLICATION NO. PCT/US99/27963	ATTORNEY'S DOCKET NUMBER MWH-0029US	
<p>17. <input checked="" type="checkbox"/> The following fees are submitted:</p> <p>BASIC NATIONAL FEE (37 CFR 1.492(a)(1) - (5)):</p> <p>Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$970.00</p> <p>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$840.00</p> <p>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$690.00</p> <p>International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$670.00</p> <p>International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$96.00</p>		CALCULATIONS PTO USE ONLY	
ENTER APPROPRIATE BASIC FEE AMOUNT =		\$ 670.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).		\$ 0.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	24 - 20 =	4	X \$18.00 \$ 72.00
Independent claims	8 - 3 =	5	X \$78.00 \$ 400.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$260.00 \$ 0.00
TOTAL OF ABOVE CALCULATIONS =		\$ 1142.00	
Reduction of 1/2 for filing by small entity, if applicable. A Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).		\$ 0.00	
SUBTOTAL =		\$ 1142.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).		\$ 0.00	
TOTAL NATIONAL FEE =		\$ 1142.00	
Fee for recording the enclosed assignment (37 CFR 1.21(b)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property		+ \$ 0.00	
TOTAL FEES ENCLOSED =		\$ 1142.00	
		Amount to be refunded: \$	
		charged: \$	
<p>a. <input type="checkbox"/> A check in the amount of \$ _____ to cover the above fees is enclosed.</p> <p>b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. <u>50-1293</u> in the amount of \$ <u>1142.00</u> to cover the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>50-1293</u>. A duplicate copy of this sheet is enclosed.</p>			
<p>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</p> <p>SEND ALL CORRESPONDENCE TO:</p> <p>Gisela M. Field Genaissance Pharmaceuticals, Inc 5 Science Park New Haven, CT 06511</p>			
<p><u>Gisela M. Field</u> SIGNATURE</p> <p>Gisela M. Field NAME</p> <p>47,562 REGISTRATION NUMBER</p>			

Practitioner's Docket No. M WH-0029US

PATENT**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Liggett, Stephen B.

Application No.: To be assigned
Filed: May 25, 2001Group No.: To be assigned
Examiner: To be assigned

For: POLYMORPHISMS IN THE 5' LEADER CISTRON OF THE BETA2-ADRENERGIC RECEPTOR

Assistant Commissioner for Patents
Washington, D.C. 20231**SECOND PRELIMINARY AMENDMENT TO CLAIMS**
(37 C.F.R. 1.121 and M.P.E.P. 714.09)

This application is the National Phase filing of PCT/US99/27963. This paper is filed to amend claims in response to the International Preliminary Examination Report (IPER) mailed on March 6, 2001 and to add new dependent claims to the current application. The accompanying first preliminary amendment cancels claims prior to the calculation of the filing fee. The additional claims presented herein are not taken into account when calculating the filing fee. Please charge any additional claims fees to our deposit account 50-1293 or credit any excess thereto.

IN THE CLAIMS

Please amend the following claims:

19. (amended) A method for determining the frequency of a B₂AR genotype or a B₂AR haplotype in a population, comprising
 - (a) determining the B₂AR genotype or the B₂AR haplotype pair for [the B₂AR 5' gene that is present in] each member of the population and
 - (b) calculating the frequency any particular B₂AR genotype or B₂AR haplotype is found in the population.
26. (amended) A method for predicting a patient's bronchodilating response to an agonist of B₂AR, which comprises determining the patient's genotype for the B₂AR 5'LC polymorphic site, wherein a patient who is homozygous T at this site is unlikely to exhibit a bronchodilating response to the agonist and a patient who contains a C at this site is likely to exhibit a bronchodilating response against the agonist.